Related Experiment Video
Updated: Jun 15, 2026
09:36
Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays
Published on: August 13, 2017
Oligomeric alpha-synuclein and its role in neuronal death
1Department of Biology and Biochemistry, University of Bath, Bath, UK. bssdrb@bath.ac.uk
IUBMB Life
|March 9, 2010
Summary
Oligomeric alpha-synuclein, not fibrillar forms, is linked to neuronal death in Parkinson's disease. Copper-binding oligomers may be the specific neurotoxic species, warranting further investigation.
Area of Science:
- Neuroscience
- Protein Biochemistry
- Neurodegenerative Diseases
Background:
- Alpha-synuclein is implicated in neurodegenerative disorders like Parkinson's disease.
- Historically, research emphasized the fibrillar form of alpha-synuclein.
- Emerging evidence suggests oligomeric forms are more cytotoxic.
Purpose of the Study:
- To review the evidence linking specific alpha-synuclein oligomers to neuronal death.
- To explore the role of copper binding in the neurotoxicity of alpha-synuclein oligomers.
Main Methods:
- Literature review of recent research on alpha-synuclein.
- Analysis of studies investigating protein oligomerization and copper binding.
- Evaluation of evidence for specific oligomeric species causing neurodegeneration.
Main Results:
- Oligomeric alpha-synuclein is increasingly recognized as the primary toxic species.
- A specific oligomer, potentially involved in copper binding, is highlighted as a key neurotoxic form.
- Evidence supports a shift in focus from fibrillar to oligomeric forms in understanding disease mechanisms.
Conclusions:
- The neurotoxic potential of alpha-synuclein lies in its oligomeric forms.
- Copper-binding interactions may be critical in mediating the toxicity of these oligomers.
- Further research into these specific oligomers is crucial for understanding Parkinson's disease pathogenesis.
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...